Interstitial nephritis with pembrolizumab: A case report and review
| Autor: | A Inoriza Rueda, O Montero Pérez, A Peláez Bejarano, M.T. Garrido Martínez |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Oncology medicine.medical_specialty Lung Neoplasms medicine.drug_class medicine.medical_treatment Interstitial nephritis 030232 urology & nephrology Pembrolizumab Antibodies Monoclonal Humanized Monoclonal antibody 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Immune system Carcinoma Non-Small-Cell Lung Internal medicine medicine Humans Pharmacology (medical) Adverse effect Lung cancer Adult patients business.industry Antibodies Monoclonal Immunotherapy Middle Aged medicine.disease 030220 oncology & carcinogenesis Nephritis Interstitial business |
| Zdroj: | Journal of Oncology Pharmacy Practice. 27:1046-1051 |
| ISSN: | 1477-092X 1078-1552 |
| DOI: | 10.1177/1078155220961553 |
| Popis: | Introduction Pembrolizumab is a monoclonal antibody approved for adult patients with advanced non–small-cell lung cancer (NSCLC). Although immune related adverse events are considered to be well tolerated, complications may occur and discontinuation of the treatment could be required. Case report A 62-year old patient diagnosed with advanced non-small cell lung cancer experienced a decline in the renal function after seven cycles with pembrolizumab. Management & outcome: After ruling out other common causes of interstitial nephritis, pembrolizumab was attributed as a cause of interstitial nephritis. At first, toxicity was managed with corticosteroids and closely monitoring the patient, but finally pembrolizumab had to be discontinued due to the kidney function did not recover. Discussion Renal and urinary disorders were reported in |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|